scholarly journals Analysis of the Onset and Mortality of Common Malignant Tumors Among Registered Residents in Xishan District in 2016

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Xuejing Xia ◽  
Dazhuo Lu ◽  
Meiqiong Jiang ◽  
Xincai Zhou ◽  
Weilin Zhang
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Mortality Rate ◽  
Malignant Tumor ◽  
Prevention And Control ◽  
Cancer Colorectal ◽  
Malignant Tumors ◽  
Female Breast Cancer ◽  
Female Breast ◽  
And Control

Objective: To analyse the cancer incidence and mortality in xishan district in 2016, and to provide scientific basis for tumor prevention and control. Methods: The 2016 malignant tumor registration report data in xishan district were collected and analysed, stratified according to gender and age, and the reported incidence of malignant tumor in xishan district was calculated and analysed (all the following incidence rates belong to the reported incidence), gender, age incidence, bid acceptance rate, mortality and other related indicators. Results: The total registered population of malignant tumor in xishan district in 2016 was 540,494 (268 553 males and 271 941 females), and 876 new cases were reported. The incidence rate was 162.07/105, the bid-winning rate was 176.39 /105, the world standard rate was 91.16/105, and the cumulative rate (0-74 years old) was 10.44%. The incidence of malignant tumors in males (159.00/105) was lower than that in females (165.11/105). Incidence increases with age, rises sharply and rapidly around age 40, and declines after reaching a peak at age 75. Lung cancer, colorectal cancer, thyroid cancer and female breast cancer are common malignant tumors in the western mountainous areas. It accounts for about 55% of the total number of new malignant tumors. In 2016, 653 people died of malignant tumors in xishan district. The mortality rate was 120.82/105 (male mortality 151.11/105, female mortality 90.46/105), the bid-winning mortality rate was 43.53/105, and the bid-winning mortality rate was 57.72/105. Lung cancer, liver cancer, colorectal cancer and stomach cancer are the malignant tumors with high mortality, accounting for about 62% of the death. Conclusion: The morbidity and mortality of malignant tumors are relatively high in xishan district, and prevention and control of lung cancer, liver cancer, stomach cancer, colorectal cancer, female breast cancer and thyroid cancer should be emphasized.

scholarly journals Promising Advances in LINC01116 Related to Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Yating Xu ◽  
Xiao Yu ◽  
Menggang Zhang ◽  
Qingyuan Zheng ◽  
Zongzong Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Lung Cancer ◽  
Cancer Colorectal ◽  
Malignant Tumors ◽  
Biological Processes ◽  
Aberrant Expression ◽  
Protein Coding ◽  
Future Studies ◽  
Non Coding Rnas

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

Changes in stage at diagnosis of screenable cancers after the Affordable Care Act.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6521-6521 ◽  
Author(s):  
Xuesong Han ◽  
Chun Chieh Lin ◽  
Ahmedin Jemal
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Cervical Cancer ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
Stage I ◽  
Stage At Diagnosis ◽  
Female Breast

6521 Background: Extensive evidence links inadequate insurance with later stage at cancer diagnosis, particularly for cancers that can be detected by screening. The Affordable Care Act (ACA) implemented in 2014 has substantially increased insurance coverage for Americans 18-64 years old. This study aims to examine any changes in stage at diagnosis after the ACA for the following cancers for which screening is recommended for individuals at risk: female breast cancer, colorectal cancer, cervical cancer, prostate cancer, and lung cancer. Methods: We used National Cancer Data Base, a nationally hospital-based cancer registry capturing 70% new cancer cases in the US each year, to identify nonelderly cancer patients with screening-appropriate age who were diagnosed during 2013-2014. The percentage of stage I disease was calculated for each cancer type before (2013 Q1-Q3) and after (2014 Q2-Q4) the ACA. 2013 Q4-2014 Q1 was excluded as a washout/phase-in period. Prevalence ratios (PR) and 95% confidence intervals (CI) were calculated using log-binomial models controlling for age, race/ethnicity and sex if applicable. Results: 121,855 female breast cancer patients aged 40-64 years, 39,568 colorectal cancer patients aged 50-64 years, 11,265 cervical cancer patients aged 21-64 years, 59,626 prostate cancer patients aged 50-64 years, and 41,504 lung cancer patients aged 55-64 years were identified. After the implementation of the ACA, the percentage of stage I disease increased statistically significantly for female breast cancer (47.8% vs. 48.9%; PR = 1.02 [95%CI 1.01-1.03]), colorectal cancer (22.8% vs. 23.7%; PR = 1.04 [95%CI 1-1.08]), and lung cancer (16.6% vs. 17.7%; PR = 1.06 [95% CI 1.02-1.11]). A shift to stage I disease was also observed for cervical cancer (47.2% vs. 48.7%; PR = 1.02 [95% CI 0.98-1.06]) although not statistically significant. In contrast, the percentage of stage I decreased for prostate cancer (18.5% vs. 17.2%; PR = 0.93 [95%CI 0.9-0.96]) in 2014. Conclusions: The implementation of the ACA is associated with a shift to early stage at diagnosis for all screenable cancers except prostate cancer, which may reflect the recent US Preventive Services Task Force recommendations against routine prostate cancer screening.

scholarly journals Socio-Economic Position, Cancer Incidence and Stage at Diagnosis: A Nationwide Cohort Study in Belgium

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 933
Author(s):  
Michael Rosskamp ◽  
Julie Verbeeck ◽  
Sylvie Gadeyne ◽  
Freija Verdoodt ◽  
Harlinde De Schutter
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cohort Study ◽  
Cancer Incidence ◽  
Regression Models ◽  
Female Breast Cancer ◽  
Stage At Diagnosis ◽  
Female Breast ◽  
Economic Parameters ◽  
Economic Position

Background: Socio-economic position is associated with cancer incidence, but the direction and magnitude of this relationship differs across cancer types, geographical regions, and socio-economic parameters. In this nationwide cohort study, we evaluated the association between different individual-level socio-economic and -demographic factors, cancer incidence, and stage at diagnosis in Belgium. Methods: The 2001 census was linked to the nationwide Belgian Cancer Registry for cancer diagnoses between 2004 and 2013. Socio-economic parameters included education level, household composition, and housing conditions. Incidence rate ratios were assessed through Poisson regression models. Stage-specific analyses were conducted through logistic regression models. Results: Deprived groups showed higher risks for lung cancer and head and neck cancers, whereas an inverse relation was observed for malignant melanoma and female breast cancer. Typically, associations were more pronounced in men than in women. A lower socio-economic position was associated with reduced chances of being diagnosed with known or early stage at diagnosis; the strongest disparities were found for male lung cancer and female breast cancer. Conclusions: This study identified population groups at increased risk of cancer and unknown or advanced stage at diagnosis in Belgium. Further investigation is needed to build a comprehensive picture of socio-economic inequality in cancer incidence.

scholarly journals Analysis of the Breast Cancer Mortality Rate in Portugal Over a Decade: Spatiotemporal Clustering Analysis

2020 ◽  
Vol 33 (5) ◽  
pp. 305
Author(s):  
Inês Afonso Gomes ◽  
Carla Nunes
Keyword(s):  
Breast Cancer ◽  
Mortality Rate ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Age Groups ◽  
Female Breast Cancer ◽  
North Coast ◽  
Special Focus ◽  
Female Breast ◽  
Spatiotemporal Clustering

Introduction: Breast cancer is the first cause of cancer-related death in Portuguese women. This study aimed to characterize female breast cancer mortality in Portugal in the period between 2002 and 2013, with a special focus on spatiotemporal patterns.Material and Methods: The breast cancer mortality rate was studied using descriptive analysis (unadjusted and age-adjusted), and spatiotemporal clustering analyses.Results: In 2002 – 2013 the breast cancer mortality rate was 28.47/100 000 inhabitants and the age-adjusted mortality rate was 19.46/100 000 inhabitants. In this period the Lisbon region (urban), Alentejo and Algarve (rural) presented higher breast cancer mortality rate, but Madeira (urban), Lisbon and Algarve had higher age-adjusted mortality rate. In the spatiotemporal analysis, the overall mortality rate showed an increasing trend of 1.218%/year, without spatial variations. Also, different patterns were detected in the < 50, 50 - 64 and ≥ 65 age-groups (+ 0.725%, - 1.781% and + 0.896%, respectively). One temporal (2004 – 2006) and one spatiotemporal cluster (North coast) presented significantly lower mortality rate than expected for the period and/or area (26.2 and 16.1/100 000 inhabitants, respectively). Conversely, two spatiotemporal clusters, located in the city of Lisbon (2002 – 2007) and in the Centre region (2008 – 2013), presented significantly higher breast cancer mortality rate than expected (48.6 and 34.9/100 000 inhabitants, relative risk: 1.74 and 1.26, respectively).Discussion: The annual female crude and adjusted breast cancer mortality rate matched previous publications. However the annual increase detected in the unadjusted rate clashes with the published literature. Overall, the presence of spatiotemporal clusters supports the uneven distribution of the breast cancer mortality reported previously in the different Portuguese regions.Conclusion: This study identified areas and trends of the female breast cancer mortality rate, showing high spatiotemporal variations that must support further detailed studies/interventions.

scholarly journals High Mortality Rate due to False Gid in a Sheep Herd

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Ali Asghar Mozaffari ◽  
Saeedeh Shojaeepour ◽  
Shahin Ghahremani Ghareh Cheshmeh
Keyword(s):  
Mortality Rate ◽  
High Mortality ◽  
Prevention And Control ◽  
Present Report ◽  
Economic Losses ◽  
Oestrus Ovis ◽  
Pathological Findings ◽  
Sheep Brain ◽  
And Control ◽  
Heavy Infestation

The sheep nasal bot, Oestrus ovis (Diptera: Oestridae), is a cosmopolitan parasite commonly found in sheep and occasionally goats. Rarely a bot will migrate into the sheep brain (false gid). Following the complaint of an animal husbandman about high mortality rate in a sheep herd, the herd was clinically, hematologically, and pathologically examined exactly. Clinical, hematological, and pathological findings were described in the text. Necropsy findings showed heavy infestation with Oestrus ovis larvae. The herd was treated with Ivermectin. After treatment all patients without nervous sings were recovered. Patients with nervous signs did not respond to treatment, but new cases of disease did not occur and the mortality stopped. In the present report, a high mortality rate due to false gid in a sheep herd was described. The prevention and control of the disease are important because of economic losses and the possibility of transmission to the human.

scholarly journals Exosomes of malignant tumors: prospects of omiсs diagnostics

2019 ◽  
Vol 65 (6) ◽  
pp. 457-467 ◽  
Author(s):  
N.A. Shushkova ◽  
S.E. Novikova ◽  
V.G. Zgoda
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Early Detection ◽  
Tumor Cells ◽  
Malignant Tumors ◽  
Molecular Study ◽  
Response To Therapy ◽  
Disease Prediction ◽  
Current Experience

The main problems in the diagnostics and treatment of malignant tumors are early detection of the disease, prediction of the course of the disease and response to therapy. The solution may be associated with identification of biomarkers secreted by tumor cells within extracellular vesicles, known as exosomes. The study of exosome proteins attracts special attention, because their molecular composition can have information about tumor identity, and also represent a set of signaling molecules that regulate the processes of tumor progression and growth. In addition, the analysis of exosomes secreted into the extracellular space corresponds to the promising concept of a liquid biopsy. In this review, we have summarized the current experience in the molecular study of exosomes in various types of malignant tumors, including colorectal cancer, lung cancer, ovaries, prostate and breast cancer, with special emphasis on omics methods and outlined the prospects for their use in diagnosis.

scholarly journals Use and Patterns of Supportive Care Among Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Colorectal Cancer, Lung Cancer, or Non-Hodgkin's Lymphoma in US Clinical Practice

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5909-5909 ◽  
Author(s):  
Derek Weycker ◽  
Amanda Silvia ◽  
Kathryn Richert-Boe ◽  
Mark Bensink ◽  
James O. Brady ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Lung Cancer ◽  
Supportive Care ◽  
Research Funding ◽  
Cancer Colorectal ◽  
Employment Equity ◽  
Myelosuppressive Chemotherapy ◽  
Study Population ◽  
Equity Ownership

Abstract Background: Supportive care with colony-stimulating factors (CSFs) and antimicrobials (AMBs) is recommended for many patients receiving myelosuppressive chemotherapy for solid tumors or non-Hodgkin's lymphoma (NHL). However, evidence on the use and patterns of pharmacotherapy given to prevent, control, or relieve complications and side effects (such as febrile neutropenia [FN]), and to improve patient comfort and quality of life, among this patient population in US clinical practice is limited. Method s: A retrospective cohort design and data from four US health systems-Geisinger Health System, Henry Ford Health System, Kaiser Permanente Northwest, and Reliant Medical Group-spanning 2009-2013 were employed. The study population comprised all patients who received myelosuppressive chemotherapy for invasive breast cancer, invasive colorectal cancer, invasive lung cancer, or NHL. Data were collected via a standardized case report form (CRF) using electronic medical records systems, administrative data warehouses, medical charts, and cancer registries, and included patient demographics and clinical profile, cancer, treatment, and outcomes. For each subject, the first qualifying chemotherapy course, and each cycle and each FN episode within the course, was identified. Supportive care included prophylactic use of CSF agents (i.e., filgrastim, tbo-filgrastim, pegfilgrastim, and sargramostim) and AMBs (including antibiotics, antifungals, and antivirals), and were characterized on a cycle-specific basis in terms of agent received, dose, route of administration, timing, and duration of administration, as appropriate. Analyses described herein were descriptive in nature, and were based on an interim dataset. Results: The study population included a total of 527 patients who received myelosuppressive chemotherapy for breast cancer (n=281), colorectal cancer (n=95), lung cancer (n=95), or NHL (n=56) (Table). Among all subjects, mean (SD) age was 60 (13) years (40% aged ≥65 years), 17% had cardiovascular disease, 16% had lung disease, and 11% had diabetes; 33% of all patients had metastatic disease (7% of these patients had metastasis to bone), and 36% had previously received myelosuppressive therapy. Forty-two percent of all patients received CSF prophylaxis in cycle 1, and 55% received CSF prophylaxis in ≥1 cycles during their course; the mean number of CSF prophylaxis cycles, among those receiving these agents, was 3.9 (mean number of cycles in total, 7.1). Most patients received prophylaxis with pegfilgrastim (66%), and the remainder with filgrastim (34%). AMB prophylaxis was administered to 5% of patients in cycle 1 and 10% of patients at any time during their course. FN incidence proportion during the chemotherapy course was 14.2%, and was highest in cycle 1 (6.6%). Conclusion: In this retrospective evaluation of patients receiving myelosuppressive chemotherapy for breast cancer, colorectal cancer, lung cancer, or NHL, less than one-half of all patients (on average) received supportive care with CSF or AMB prophylaxis beginning in cycle 1 and few additional patients received CSF/AMB prophylaxis in subsequent cycles. FN was not uncommon, especially in the first cycle. Careful consideration should be given to identifying patients within this population who are at elevated risk of FN to ensure appropriate use of supportive care. Disclosures Weycker: Amgen, Inc.: Research Funding. Silvia:Amgen, Inc.: Research Funding. Richert-Boe:Amgen, Inc.: Research Funding. Bensink:Amgen, Inc.: Employment, Equity Ownership. Brady:Amgen, Inc.: Research Funding. Lamerato:Amgen, Inc.: Research Funding. Lipkovich:Amgen, Inc.: Research Funding. Siddiqui:Amgen, Inc.: Research Funding. Chandler:Amgen, Inc.: Employment, Equity Ownership.

scholarly journals Global, regional, and national mortality trends of female breast cancer by risk factor, 1990–2017

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui Liu ◽  
Wenjie Shi ◽  
Zhi Jin ◽  
Rui Zhuo ◽  
Jie Dong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Alcohol Use ◽  
Mortality Rate ◽  
Temporal Trends ◽  
High Body Mass Index ◽  
Female Breast Cancer ◽  
Effective Control ◽  
Female Breast ◽  
Obesity And Diabetes

Abstract Background Female breast cancer (FBC) is a malignancy involving multiple risk factors and has imposed heavy disease burden on women. We aim to analyze the secular trends of mortality rate of FBC according to its major risk factors. Methods Death data of FBC at the global, regional, and national levels were retrieved from the online database of Global Burden of Disease study 2017. Deaths of FBC attributable to alcohol use, high body-mass index (BMI), high fasting plasma glucose (FPG), low physical activity, and tobacco were collected. Estimated average percentage change (EAPC) was used to quantify the temporal trends of age-standardized mortality rate (ASMR) of FBC in 1990–2017. Results Worldwide, the number of deaths from FBC increased from 344.9 thousand in 1990 to 600.7 thousand in 2017. The ASMR of FBC decreased by 0.59% (95% CI, 0.52, 0.66%) per year during the study period. This decrease was largely driven by the reduction in alcohol use- and tobacco-related FBC, of which the ASMR was decreased by 1.73 and 1.77% per year, respectively. In contrast, the ASMR of FBC attributable to high BMI and high FPG was increased by 1.26% (95% CI, 1.22, 1.30%) and 0.26% (95% CI, 0.23, 0.30%) per year between 1990 and 2017, respectively. Conclusions The mortality rate of FBC experienced a reduction over the last three decades, which was partly owing to the effective control for alcohol and tobacco use. However, more potent and tailored prevention strategies for obesity and diabetes are urgently warranted.

Sign in / Sign up

Export Citation Format

Share Document